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Page 1 of 16 Lab on a ChipThis paper describes the fabrication and use of a microfluidic 
device for performing whole-animal chemical screens using 
non-invasive electrophysiological readouts of neuromuscular 
function  in  the  nematode  worm,  C.  elegans.  The  device 
consists of an array of microchannels to which electrodes are 
attached to form recording modules capable of detecting the 
electrical activity of the pharynx, a heart-like neuromuscular 
organ involved in feeding. The array is coupled to a tree-like 
arrangement  of  distribution  channels  that  automatically 
delivers one nematode  to each recording module. The same 
channels are then used to infuse the recording modules with 
test  solutions  while  recording  the  electropharyngeogram 
(EPG) from each worm with sufficient frequency resolution to 
detect  each  pharyngeal  contraction.  The  device  accurately 
reported  the  acute  effects  of  known  anthelmintics  (anti-
nematode  drugs)  and also correctly  distinguished a specific 
drug-resistant mutant strain of C. elegans from wild type. The 
approach  described  here  is  readily  adaptable  to  parasitic 
species for the identification of novel anthelmintics. It is also 
applicable  in  toxicology  and  drug  discovery  programs  for 
human  metabolic  and  degenerative  diseases  in  which  C. 
elegans is used as a model.
Introduction
Whole-animal  screens  in  small  model  organisms  are  gaining 
acceptance  as a means to augment traditional screens based on 
cultured  cells  and  single-celled  organisms1.  The  trend toward 
whole animal screening is driven in part by advances in genome 
sequencing,  which have revealed a high degree of  genetic and 
biochemical conservation between humans and small, genetically 
tractable  organisms  such  as  the  nematode  Caenhorhabditis 
elegans2,  the  fruit  fly  Drosophila  melanogaster3-5,  and  the 
zebrafish Danio rerio6. A second factor driving this trend is the 
integration of  systems for computerized detection of  chemically 
induced phenotypes with systems that automatically move and 
sort test organisms7-11. As a result, whole-animal testing can now 
be  done  earlier  in  the  drug  development  pathway  than  ever 
before,  in  some  cases  as  early  as  the  primary  screening  of 
compound  libraries1,  9.  This  change  is  significant  because 
compounds in  whole-animal screens are  tested at  the  level of 
functional multicellular units including synapses,  muscles,  and 
organs  rather  than  isolated  cells.  Thus,  promising  compounds 
(leads) are more likely to succeed in subsequent phases of  drug 
development.
The  ability  of  an  automated  screening  method  to 
identify  leads depends critically upon the  objective  parameters 
that form the basis of the screen. Such parameters, called readouts 
or end-points,  have  therefore  been the  targets of  considerable 
ingenuity. Readouts fall into two broad categories: (1) assessment 
of the quantity or anatomical disposition of a fluorescent marker 
at the cellular12-14 or organismal15, 16 level, and (2) quantification 
of stereotypic behaviors such as crawling17, 18, swimming19, 20, or 
egg laying21.
Each type of  readout represents a unique compromise 
between cost and information content. The information content of 
fluorescent-marker  readouts  is  generally  low12  unless  image 
analysis is used15,  22, but the latter usually requires using a high 
numerical aperture objective lens with short working distance and 
narrow  field  of  view,  which makes  this method  expensive  to 
parallelize  for  whole-animal  screens.  Behavioral  readouts,  by 
contrast,  can be obtained with inexpensive optics and thus are 
more easily parallelized. However, behavioral readouts typically 
provide less information about the target of drug action because a 
given behavioral phenotype can be generated by many different 
biological mechanisms (e.g., cessation of  locomotion can result 
from  mechanisms  as  divergent  as  ion-channel  blockade  and 
disruption of  cellular respiration). This drawback can lead to a 
high  rate  of  detection  of  compounds  that  ultimately  prove 
unsuitable for use as drugs (false-positives). Thus, there is a need 
for readouts that provide more direct information about the target 
of drug action, and are practical to parallelize.
Here we present a new whole-animal screening method 
that  uses  a  non-invasive  electrophysiological  readout  of 
neuromuscular  function. The screen is based on monitoring the 
activity of the nematode throat (pharynx), a muscular pump that 
contracts rhythmically to draw liquid nutrients into the digestive 
tract  during  feeding.  As  in  the  vertebrate  heart,  rhythmic 
contractions of  the nematode pharynx are generated primarily by 
the  pharyngeal  muscles  themselves,  and  each  contraction  is 
associated with an action potential, a large voltage transient that 
can be recorded by electrodes placed on the surface of the body23. 
By  analogy  to  an  electrocardiogram,  such  a  recording  in 
nematodes is called an electropharyngeogram (EPG). In addition 
to registering  action potentials  in the pharyngeal  muscles,  the 
EPG also registers the activity of neurons that regulate the rate of 
pharyngeal  pumping in much the  same way as the autonomic 
nervous system regulates the vertebrate heart. Thus, the EPG can 
be used to investigate the effects of  drugs that act on neurons as 
well as muscles.
Using  soft-lithography,  we  constructed a  device  that 
permits simultaneous recording of  EPGs from  eight nematodes 
before, during, and after delivery of a test compound. To validate 
the utility of  the device, we demonstrate here that it rapidly and 
reliably detects the acute effects of anthelmintics (anti-nematode 
drugs) and also correctly distinguishes a specific drug-resistant 
mutant  strain  of  C.  elegans  from  wild  type.  In  addition  to 
facilitating  the  search  for  new  anthelmintics,  the  device  is 
expected to be useful in two broad areas: toxicology and drug 
discovery programs,  in which C. elegans serves as a model for 




Conventional EPG recording method
In  the  conventional  EPG  recording  method23,  the  worm  is 
immersed in  a  bath  of  physiological saline  and sucked into a 
saline-filled glass pipette (Fig. 1). Pharyngeal activity is induced 
by adding the neuromodulator serotonin to the bath saline, which 
initiates feeding behavior in C. elegans24. Because the saline is 
conductive, electrodes in the bath and the pipette are in electrical 
contact with the surface of  the body. The conventional method is 
ill-suited to drug screens in two key respects. First, to attain this 
recording configuration, the operator must capture the worm by 
manual adjustment of  a micromanipulator that holds the pipette 
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and parallelize. Second, drugs are delivered via the bath solution, 
thus requiring macroscopic volumes of drug solutions. 
Microfluidic EPG device
To  adapt  EPG  recording  approach  for  drug  screening,  we 
constructed a  device that automatically loads individual worms 
into eight recording modules for  simultaneous EPG  recording 
from  multiple worms (Fig. 2A). The device is fabricated from a 
single  layer  of  polydimethylsiloxane  (PDMS),  using  standard 
methods of  soft-lithography25,  26 and bonded to a glass substrate 
after exposure to an air plasma. The array of recording modules is 
served  by  a  bifurcating,  tree-like  arrangement  of  distribution 
channels.  When a buffer solution containing worms is injected 
into the inlet port of  the device, the solution flows through all 
open  channels,  causing  animals  to  segregate  passively  into 
separate recording modules until each is blocked by a worm8.
Within each recording module, the worm is carried  by 
the flowing fluid until it reaches a constriction (henceforth “trap”) 
into which only the worm's head or tail, which are narrower than 
the  rest of  the body,  can fit.  The  trapped worm  obstructs the 
worm  channel,  diverting  most  of  the  flow  into  the  side-arm 
channel. This arrangement allows test solutions injected into the 
inlet port to continue to flow past the trapped worms while the 
EPG is recorded. Two waste reservoirs collect perfusate from the 
worm   trap  and  side-arms,  respectively.  For  long-term 
experiments ( >6 h), the capacity of  the waste reservoirs can be 
increased by inserting tight-fitting glass tubes.
Electrical  recordings  are  made  by  means  of  metal 
electrodes inserted into the worm  electrode ports and the joint 
inlet/reference  electrode  port  (Fig.  2A).  Each  of  the  worm 
electrodes is connected to the positive input of  one of a bank of 
eight  differential  amplifiers  (see  Experimental  Methods).  The 
common reference electrode is connected to the negative inputs 
of  all amplifier channels.  The  reference electrode is hollow to 
permit perfusion of test solutions during EPG recordings.
To optimize electrical recordings and solution delivery, 
it is important that the head or tail of  the worm  enters the trap 
rather than one of  the  side-arm  openings. Three aspects of  the 
design ensure that this happens. First, the dimensions of the side-
arm  channel openings (10 µm  × 20 µm) are small compared to 
the diameter of  the worm  (70 – 90 µm). Second, dimensions of 
channels leading away from  the  recording module  are adjusted 
such that the calculated hydrodynamic resistance to flow through 
the side arms to Reservoir 2 is 20 times the resistance to flow 
through the worm  trap to Reservoir 1. Thus, as a worm  enters a 
recording module, ~95% of  the flow is toward the worm  trap 
rather than the side arms. Third, the funnel-shaped entrance to the 
worm  trap aligns the worm  so that its head or tail is driven into 
the  trap  (Fig.  2E).  The  design  of  the  recording  module  thus 
ensures a snug fit of the worm in the trap, creating a sufficiently 
large electrical resistance (Rseal) to record the EPG with a high 
signal-to-noise  ratio  (SNR;  Fig.  2D),  without  unduly 
compromising the flow of test solutions around the worm. 
Worms were held in position throughout an experiment 
by positive pressure exerted by solutions perfused into the device 
via a syringe pump. Flow rate was adjusted so that approximately 
one third of  the pharynx  of  a headfirst worm  remained in the 
funnel-shaped region of  the worm channel where it was exposed 
to perfused solutions. During tailfirst recordings, a similar length 
of the worm’s body was lodged in the worm  trap, and the head 
was completely exposed to the solution. The optimum flow rate 
depended on the relative size of  the worm  and the worm  trap, 
with the effective range of  flow rates for young adult C. elegans 
being approximately 5 to 50 µL/min. Below this range, the SNR 
was too low (e.g., Fig. 2D); above this range, the worm was often 
forced  through  the  trap.  Under  typical  recording  conditions, 
median SNR was 100 (n = 7), which was sufficient to observe 
detailed features of the EPG recordings. 
Results and Discussion
Parallel microfluidic electropharyngeograms
The waveforms of  EPGs recorded using the microfluidic device   
were similar to those obtained using conventional EPG recording 
methods23,  24,  27-30  (Fig 3A,B). The EPGs recorded from  worms 
oriented tailfirst in the trap were similar to EPGs from  headfirst 
worms except that the polarity was reversed23.  Referring to the 
canonical headfirst recording configuration (Fig. 3A, B), the most 
prominent features were a positive spike (E), caused by the rapid 
depolarizing phase of  the pharyngeal muscle action potential that 
initiates contraction, and a negative spike (R) caused by the rapid 
repolarization  of  the  pharyngeal  muscle  that  terminates  the 
contraction23.  Smaller  downward  peaks,  which  have  been 
attributed  to  activity  of  neurons  that  modulate  pharyngeal 
pumping23, were often visible between E and R transients. 
The  array  of  recording  modules  made  it possible  to 
record from eight worms at a time (Fig. 3C), but in some cases 
not  all  were  usable.  Overall,  the  probability  that  a  recording 
module  yielded  a  usable  EPG  recording  was 0.75  (N  =  348 
modules).  The most common cause of recording failure was an 
air bubble between the worm and one of  the electrodes. In other 
cases, a worm failed to pump or there was more than one worm in 
the module. In standard saline (M9-5HT buffer, see Experimental 
Methods), pharyngeal pumping and EPG recordings such as those 
in Fig. 3C typically continued for 6 to 8 hours and, although not 
investigated  systematically,  sometimes  overnight.  Thus,  the 
device is suitable for medium-throughput experiments involving 
acute  or  semi-chronic  exposure  of  multiple  worms  to  small 
volumes of test compounds.
Delivery of test compounds
To demonstrate the ability to record EPGs in the presence of test 
compounds,  we  perfused  the  anthelmintic  ivermectin  during 
simultaneous  EPG  recordings  from  six  worms  (Fig.  4A). 
Ivermectin  inhibits  pharyngeal  muscles  and  extrapharyngeal 
neurons  by  activating  a  class  of  glutamate-gated  chloride 
channels  located  in  the  plasma  membrane31,  32.  Perfusion  of 
ivermectin blocked  pharyngeal activity  within 10-15  min28,  33, 
regardless  of  whether  the  worms  were  oriented  headfirst  or 
tailfirst.  Pharyngeal  activity  was  unaffected  in  worms  that 
underwent a mock solution change (Fig. 4B), indicating that the 
cessation  of  activity was specific  to the presence  of  the  drug. 
Pharyngeal activity persisted in ivermectin-resistants mutants in 
which the three main muscular and neuronal targets of ivermectin 
are altered32 (Fig. 4C), indicating that the full effect of ivermectin 
in the EPG device requires the presence of previously established 
molecular targets. EPGs recorded in ivermectin also exhibited the 
expected reduction in the amplitude of  the  E and R spikes28,  33 
(Fig. 5A). We conclude that test compounds reach the worms and 
have the expected pharmacological effects, for both headfirst and 
tailfirst orientation of the worm in the trap.
  In  addition,  we  detected  two  previously  unreported 
effects  of  ivermectin.  First,  we  observed  a  reduction  in  the 
duration  of  the  action  potentials,  measured  as  the  interval 
between pairs of  E and R  spikes (Fig.  5A; see Fig.  6 below). 
Second, we observed an increase in the frequency of gaps in the 
otherwise  regular  pattern of  action potential  firing  (Fig.  5B). 
Changes in action potential duration and appearance of gaps have 
been  reported in  mutants  with loss  of  function defects in the 
molecular  target  of  the  anthelmintic  emodepside29,  34.  This 
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classes of anthelmintics.
Analysis of action potential waveform
Automated  data  analysis  is  an  essential  component  of  many 
practical screening approaches and such analysis methods have 
recently been introduced for EPG data29,  34. In addition to being 
objective  and  efficient,  automated EPG  analysis  can measure 
parameters that provide valuable insights into the mode of action 
of  a  given  test  compound34.  To  demonstrate  application  of 
automated  methods  to  EPG  recordings  obtained  in  the 
microfluidic EPG device, we quantified EPG records using three 
common  metrics  of  pharyngeal  activity:  (1)  peak-to-peak 
amplitude, defined as the voltage difference between the E and R 
peaks;  (2)  instantaneous  pumping  frequency,  defined  as  the 
reciprocal of the time between successive E peaks; and (3) action 
potential duration, defined as the time interval between the E and 
R peaks in a single pumping event. Ivermectin caused a gradual 
reduction all three measures (Fig. 6). The plot of  instantaneous 
pumping frequency also revealed the  appearance of  many low 
frequency events as the drug began to take effect (Fig. 6B, 20 – 
40 min).  Inspection of  the  raw data  showed that  these events 
corresponded to the above-mentioned gaps in the regular firing 
pattern of action potentials (Fig. 5B). Each of  the effects shown 
in  Fig.  6  is  consistent  with  the  activation  of  an  inhibitory 
conductance in pharyngeal muscles, and is thus in agreement with 
the previously established mechanism  of  ivermectin activity31 . 
This finding illustrates the utility of the present method in mode 
of action studies. 
Analysis of EPG amplitude
 A u t o m a t e d   a n a l y s i s   o f   E P G   d a t a   i s   s e n s i t i v e   t o  
variations in action potential waveform across individual worms, 
and  over  time  in response  to test compounds29.  This problem 
arises  because  extraction  of  spike  frequency  and  related 
parameters requires the use of  peak detection algorithms which 
can be  sensitive to the shape  and amplitude  of  the underlying 
events.  Although  this  sensitivity  can  be  mitigated  to  a  large 
degree  by  customizing  the  peak  detection  algorithm  for  each 
worm, doing so on the large data sets generated by parallel EPG 
recordings  may be  impractical in some  screening applications. 
Here we show that simply computing the magnitude of the EPG 
signal  can  be  diagnostic  for  the  effects  of  drugs  and genetic 
backgrounds (Fig. 7). We computed EPG magnitude by taking the 
absolute value of  the voltage at each time point and smoothing 
the  result  (see  Experimental  Methods).  The  background noise 
level, measured when pharyngeal pumping had stopped, was then 
subtracted,  yielding a  time  series that we refer to as ||EPG||(t). 
This time series compactly represents two of the main features of 
each EPG recording, changes in the amplitude and frequency of 
action potentials over time. In Fig. 7A-C, ||EPG||(t) is plotted for 
three individual worms,  one  from  each of  the three conditions 
shown  in  Fig.  4.  Group  data  were  obtained  by  normalizing 
individual ||EPG||(t) data to a value of 1 immediately prior to the 
solution change, then averaging across worms.
  Fig.  7D  shows  group  data  for  the  three  conditions 
studied in the experiment of Fig. 4. All three curves were widely 
separated relative to the standard error of the mean, showing that 
the effects of  ivermectin on wild type  and ivermectin-resistant 
mutants were  quantitatively different,  even with small  sample 
sizes (≤ 6 animals per group; see figure legend for statistics). The 
amplitude  of  the  EPG in control  animals increased over time. 
Although further  experiments  are  required,  we  speculate  that 
worms  were  gradually  pushed  further  into  the  traps  as  time 
progressed, increasing Rseal. 
  Fig.  7E  shows  a  similar  experiment  in  which  the 
anthelmintic  levamisole  was  used  instead  of  ivermectin.   As 
expected35, levamisole also caused rapid and complete reduction 
of  ||EPG||(t).  Significantly,  the  ion  channels  that  levamisole 
targets are present on body wall muscles36 and are not required 
for  normal pharyngeal pumping37.  Thus,  the  microfluidic EPG 
device  can detect anthelmintic drug activity even when a drug 
may be acting primarily at extrapharyngeal sites. We also found 
that,  in  contrast  to  the  effects  of  ivermectin,  the  effects  of 
levamisole on wild type and imvermectin-resistant mutants were 
indistinguishable (see figure  legend for statistics). This finding 
indicates that the EPG device could be used to characterize the 
effects of  drugs on a wide range of  resistance mutants or other 
genetic  backgrounds  that  could  be  useful  in  assigning  test 
compounds to existing (or novel) modes of action.
Conclusions
The device presented here permits simultaneous, individualized 
recordings  of  electrical  activity  from  up  to  eight  nematodes 
during the  application of  drugs and other  test compounds. The 
number  of  simultaneous  recordings  could  be  increased  by 
recording  from  many  devices  in  parallel,  by  increasing  the 
number of  recording modules per device, or both. The practical 
limit to the throughput of  the microfluidic EPG approach is not 
yet known,  but distribution channels for positioning more than 
100 nematodes at a time have been demonstrated8.
Modifications  to  the  current  design  using  existing 
technology  could  enhance  its  utility.  For  large  numbers  of 
simultaneous  recordings  it  would  be  advantageous  to  add 
microfabricated electrodes38 to facilitate automated connection to 
the recording equipment. The quantity of test compound required 
could  be  reduced  by  incorporating  on-chip  drug  reservoirs. 
Importantly,  the  dimensions  of  distribution  channels  and 
recording  modules  could  be  adjusted  to  accommodate  other 
species of nematodes. This modification would allow for direct, 
medium-throughput assessment of compounds to treat nematodes 
in a wide range of hosts from plant to humans39.
Experimental Methods
Nematodes
C.  elegans strains  were grown  on Nematode  Growth Medium 
(NGM) agar  plates seeded with the OP50  strain of  E.  coli. All 
strains were obtained from  the  Caenorhabditis Genetics Center 
(CGC; Minneapolis, MN). Wild-type worms were Bristol N2 and 
Ivermectin  (IVM)  resistant  mutants  were  DA1316  avr-14
(ad1302);  avr-15(ad1051);  glc-1(pk54).  Adult  hermaphrodites 
were  used  for  all  experiments  with  the  exception  of  SNR 
measurements,  which also included some L4 animals. Animals 
were  age-synchronized by  one  of  two  methods: (1)  L4s were 
transferred to a seeded NGM  plate and left overnight at room 
temperature  to  develop  into adults;  or  (2)  gravid  adults  were 
placed on seeded NGM  plates to lay eggs for  ~6 hr  and then 
removed, with the plates maintained at room temperature until the 
adults matured.
Device Fabrication
We fabricated devices using standard soft lithographic methods25, 
26f. Briefly, a silicon wafer master for the device was created by 
exposing  a  55  µm  layer  of  SU-8  2050  resist  (Microchem, 
Newton, MA) through a transparency mask and dissolving away 
unexposed material. Masters were replica-molded in PDMS, Dow 
Corning  Sylgard  184,  Corning,  NY)  and  treated  with 
chlorotrimethylsilane  (Aldrich,  St.  Louis,  MO)  to  prevent 
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reservoirs were formed using biopsy punches of  the appropriate 
diameter  (ports and inlets,  1.5 mm; reservoirs,  5  mm).  PDMS 
castings were bonded to glass substrates after 30 sec exposure to 
an oxidizing air plasma. After bonding, the capacity of each fluid 
reservoir was increased by inserting a 1.5 cm  length of  5 mm 
glass tubing.
Solutions
All  experiments  utilized  M9  buffer40 c o n t a i n i n g  K H 2PO4, 
NaHPO4, NaCl and MgSO4, to which serotonin (5HT) was added 
to stimulate pharyngeal pumping23.  Stocks of  serotonin creatine 
sulfate  monohydrate  (Sigma  H7752;  St.  Louis,  MO)  were 
prepared in M9 buffer at 40 mM and held in small aliquots at 
-20°C until use. Each day of an experiment, a fresh aliquot was 
thawed and diluted to 10 mM 5HT in M9 buffer. This “M9-5HT” 
buffer  was  the  control  medium  to  which  drugs  or  other 
compounds were added. Stock solutions of  ivermectin (10 mM; 
Sigma 8898) were made up in 100% dimethyl sulfoxide (DMSO; 
Fisher D-136; Fair Lawn, NJ) and held at -20°C  for no longer 
than  2  wk.  Control  experiments  (not  shown)  indicated  that 
DMSO at the final concentrations used for perfusions (≤ 0.1%) 
did  not  adversely  affect  EPG  activity.  Stock  solutions  of 
levamisole hydrochloride (100 mM; Sigma 31742) were made up 
in  sterile  dH20  and  maintained  at  4°C.  On  the  day  of  an 
experiment,  IVM  or  LEV  stocks  were  diluted  to  the  final 
concentration  in  M9-5HT  buffer  that  contained  0.005%  Fast 
Green (Fisher F-99) as a visual indicator of drug flow within the 
device (see below); the dye-containing buffer was filtered (PALL 
Life  Sciences 25mm  Acrodisc  syringe  filter  with 0.2  µm  HT 
Tuffryn  Membrane;  Port Washington,  NY)  before  adding  test 
compounds. 
Loading worms into the device
Young adult worms were transferred from  growth plates into a 
glass well containing M9-5HT buffer and left to acclimate for 10 
min.  While  viewed  under  transillumination  on  a  Stemi  SV6 
binocular stereomicroscope (Carl Zeiss Inc., Thornwood, NY), 8 
worms were picked using a  loop tool and placed into the inlet 
port  of  the  device,  which  had been  preloaded  with M9-5HT 
buffer. A 3 cc syringe filled with M9-5HT buffer connected to a 
length of 1.5 mm  polyethylene tubing was then inserted into the 
inlet port and gentle pressure was applied to propel worms into 
the  eight individual worm  channels in  the  device.  The tubing 
connected to  the  inlet  port was  then  removed  and the loaded 
device was moved to the EPG recording apparatus.
Electrophysiological recordings
EPGs  were  recorded  by  a  pair  of  4-channel  AC  differential 
amplifiers (A-M Systems model 1700, Carlsborg, WA) connected 
to electrodes inserted into the device. Electrodes were made from 
0.5 inch long passivated 17 gauge stainless steel tubes (0.058 inch 
OD, 0.0475 inch ID, New England Small Tube, Litchfield, NH). 
Recordings were  made at voltage gains of  1,000×  or 
10,000× and filtered with a low-pass cutoff of 1.0 Hz and a high-
pass cutoff of 5 kHz. Signals were further conditioned by a 60 Hz 
notch  filter.  Signals were  displayed  on a  pair of  four channel 
oscilloscopes (TDS 2024B, Tektronix, Beaverton, OR) at a sweep 
speed  sufficient  to  resolve  the  components  of  individual 
pharyngeal  action  potentials.  Signals  were  recorded  for  later 
analysis  using  a  data  acquisition  system  (Micro1401-3, 
Cambridge Electronic Design (CED), Cambridge, UK) connected 
to a  computer running  Spike2 software  (version 7.06a,  CED). 
Data were  sampled at 5 or  10 kHz  per channel.  An additional 
channel was used as a keystroke-controlled event marker (e.g., 
time of drug delivery). Data were typically acquired continuously 
in Spike  2, beginning   when electrodes were inserted into the 
device  and  continuing  until  an  experiment  was  terminated 
(generally 1-2 h after drug addition). For long recording sessions 
(e.g., overnight), Spike2 was set to acquire short data segments at 
regular intervals (e.g., 5 min of recording every 20 min). 
Solution delivery 
Solutions were  delivered  to EPG  devices via  a  syringe  pump 
(Harvard Apparatus PHD 2000; Holliston, MA) driving a pair of 
3 cc syringes. One syringe was filled with M9-5HT buffer while 
the other contained M9-5HT buffer with 0.005% Fast Green to 
which was added nothing (for control experiments), drug, drug 
plus vehicle or vehicle alone. Each syringe was fitted with a 25 
gauge stub needle that led via a 30 cm length of fine polyethylene 
tubing  (BPE-T25,  Instech  Solomon,  Plymouth  Meeting,  PA, 
USA)  to  the  hollow  metal  reference  electrode  (see  above). 
Following  pilot  experiments  investigating  the  relationship 
between perfusion rate and EPG signal-to-noise (SNR) ratio (see 
Results), a perfusion rate of  6 µl/min was used. Solution changes 
were effected by removing the reference electrode connected to 
the  first  syringe  from  the  fluid  inlet  port  of  the  device  and 
inserting the reference electrode connected to the second syringe. 
This procedure eliminated potential cross-contamination between 
solutions. The perfusion line from the syringe not in use was led 
to  a  waste  receptacle.  The  latency  between  insertion  of  the 
electrode and arrival of  the new solution at the worm's location, 
as visualized by dye movement, was approximately 60 sec. The 
electrical  artifact  from  switching  reference  electrodes  was 
subsequently blanked from recordings shown in Figures.
Calculation of ||EPG||(t)
A  simple  analysis,  which  did  not  involve  identifying  the 
occurrences of  individual pharyngeal contractions, was used to 
quantify the decline in the EPG amplitude with time after drug 
application. For this analysis  EPG(t) was band-pass filtered in 
Spike2 (2 – 200 Hz, 2-pole Bessel filters), down-sampled at 500 
Hz,  full-wave rectified,  and smoothed (exponential  filter,  time 
constant = 60 s), to yield ||EPG||(t), a measure that is proportional 
to both the frequency and strength of pharyngeal contractions. In 
experiments  during  which  pharyngeal  pumping  ceased 
completely for a period of time, the baseline noise was removed 
by  subtracting  the  minimum  value  of  ||EPG||(t)  during  the 
experiment. The mean baseline noise determined in this way was 
3.7 ± 0.5 µV (mean ± S.D., n = 24 worms).  In experiments in 
which pharyngeal pumping never ceased, the baseline noise was 
assumed to be 3.7 µV.
Analysis of EPG features
To analyze the effects of test solutions on frequency, strength, and 
other aspects of pharyngeal pumping separately, we identified the 
onset  of  pharyngeal  muscle  contraction  and relaxation  during 
each pump cycle (Fig. 3). For this analysis, we inverted the sign 
of EPGs obtained from  worms that were oriented tail-first in the 
recording  chamber.  EPGs  were  high-pass  filtered  to  aid  in 
separating the E and R peaks from the slower components of the 
EPG waveform and from low-frequency noise before locating all 
positive  and  negative  peaks  that  exceeded  threshold  values.. 
Event  times  were  then  measured  as  the  times  of  the 
corresponding peaks in the unfiltered EPG. Positive and negative 
thresholds and high-pass filter frequencies were set by the user 
for each worm. Valid EPG events were defined as a positive peak 
followed  by  a  negative  peak  with  no  intervening  positive  or 
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interval  between  the  positive  and  negative  peaks,  which 
corresponds to the duration of  the contraction of the pharyngeal 
muscles23,  and the voltage difference between the positive and 
negative peaks (peak-to-peak amplitude), which reflects the size 
and speed of  the muscle  depolarization and repolarization. The 
peak-to-peak amplitude is also sensitive to changes in Rseal. We 
measured pump frequency as the reciprocal of  the time interval 
between the positive peaks of successive valid EPG events.
Calculation of SNR
Signal to noise ratio was defined as SNR = (σ T
2 −σN
2 )/σN
2 , where 
σ T
2  was the total variance of  the EPG recording during vigorous 
pumping (~5  Hz)  and σN
2 was  the  variance  during periods in 
which pumping spontaneously ceased.
Measurement of Rseal
We determined typical values for  (Rseal) by applying a voltage 
step between the positive electrode for a recording module and 
the  common  reference  electrode,  and  measuring  the  resulting 
electric current. Because of  the small cross-sectional area of the 
channels in the microfluidic device, the electrical resistance was 
relatively high even when the recording channel was unoccupied 
by a worm (~5 MΩ). This resistance increased to ~6 MΩ with a 
worm  loosely positioned in the channel, and typically increased 
by ~200 kΩ with the worm  snugly in the trap, from  which we 
estimate that Rseal ≈ 200 kΩ, similar to seal resistances obtained 
in “loose-seal”  patch  recordings41.  Given  the  relatively  small 
value  of  Rseal  compared  to  the  resistance  of  the  unoccupied 
channel, is perhaps surprising that the SNR increased 9-fold when 
the worm’s head entered the trap, but this result is consistent with 
the conclusion that EPG is primarily the result of current flowing 
out of the mouth23, which becomes electrically isolated from the 
rest of  the body when the head is held snugly in the trap. It is 
unclear why the SNR also increased greatly when the tail of the 
worm  entered the trap, but we  speculate that the  major  return 
current pathway for the EPG may be through the worm’s anus.
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Figure 1. Diagram of the conventional method of recording an 
electropharyngeogram (EPG). A worm is submerged in a bath of 
physiological saline and the anterior end is sucked into a tight-
fitting, saline-filled glass pipette. The tight apposition between 
the worm's body and the mouth of the pipette generates an 
electrical resistance (Rseal) between the lumen of the pipette and 
the bath. As a result of this resistance, electrical currents 
generated by pharyngeal activity can be detected directly, or by 
means of the voltage difference (V) that is generated between the 
pipette and the bath23. The microfluidic EPG device described in 
Fig. 2 replicates the recording topology illustrated here.
Figure 2. Design of the microfluidic EPG device. A. Top view of 
the overall device. Arrows indicate the direction of fluid flow. B. 
Top view of a single recording module. The inset shows the 
funnel-shaped entrance to the worm trap and position of the head 
of the worm in the trap under headfirst recording conditions. 
Color indicates feature height (black, 50 µm; gray, 10 µm). C. 
Three dimensional rendering of the recording module. D,E. 
Enhancement of signal-to-noise ratio (SNR) by positioning worm 
snugly in the worm trap. D. Micrograph of the recording module 
and the associated EPG recording with the syringe pump turned 
off. E. Micrograph of the recording module and the associated 
EPG recording with the syringe pump turned on, forcing the 
worm's head into the trap. Anterior is to the right and the 
recordings are shown on the same vertical scale in both panels. In 
D and E, arrowheads indicate the posterior margin of the 
pharynx.
Figure 3. EPG recordings obtained by the conventional method 
and the microfluidic device. A. Pharyngeal action potential 
recorded using the conventional method shown in Fig. 1 
(reproduced from Fig. 2A of reference23). E and R indicate the 
large positive (Excitatory) and negative (Relaxation) spikes, 
respectively, at the beginning and end of the action potential. The 
worm was oriented headfirst in the pipette. B. Pharyngeal action 
potential recorded using the microfluidic EPG device. Symbols 
and worm orientation are as in A. The scale bar in B refers to A 
and B. C. Simultaneous recordings from 8 worms in a single 
microfluidic EPG device. All worms except 2 and 8 were oriented 
headfirst in the worm trap. Vertical scales (voltage) were adjusted 
to produce similar signal amplitudes in all traces. The data on the 
left are duplicated at right on a compressed time axis, to illustrate 
how recordings are displayed in Figs. 4 and 7.
Figure 4. Ivermectin effects on wild type and ivermectin-resistant 
worms. Each panel shows simultaneous EPG recordings from a 
single microfluidic EPG device, each containing both headfirst 
and tailfirst worms. Dashed lines replace data segments obscured 
by electrical artifacts during the solution change. Vertical scales 
(voltage) were adjusted to produce similar signal amplitudes in 
all traces; the horizontal scale bar (time) in C applies to all 
panels. In all experiments, worms were first perfused with control 
solution (M9-5HT buffer for >30 min before switching to drug or 
control solution containing 0.005% Fast Green as a visual marker. 
A. 3 µM ivermectin rapidly blocked EPG activity in wild type 
worms. B. EPG activity continued robustly during mock solution 
change in wild type worms. C. 3 µM ivermectin only partially 
inhibited EPG activity in ivermectin-resistant mutant worms 
(DA1316 avr-14(ad1302); avr-15(ad1051); glc-1(pk54))
compared to wild type worms (compare with A). 
Figure 5. Changes in EPG waveform and frequency during 
ivermectin treatment.  A and B each show representative 
recordings from a single wild type worm at the times indicated at 
left, relative to the switch from control solution to ivermectin 
(designated 0 min). Vertical gain (voltage) is the same for all 
traces within a panel. A. Changes in EPG waveform. This worm 
was headfirst in the channel and EPG traces are aligned (vertical 
dashed line) by the onset of a positive E spike, except for the 
bottom trace which occurred after EPG activity ended. The 
ivermectin concentration was 10 µM. Filled bars show E-to-R 
duration for each action potential waveform; filled circles 
indicate action potentials waveforms with an E but no R spike; 
open bars indicate voltage excursion of EPG waveforms in in the 
adjoining trace. The EPG Action potentials waveform became 
progressively smaller and briefer, pumping frequency decreased 
and the R spike of the waveform was lost. B. Changes in action 
potential timing. In control solution, pumping was regular in 
frequency and large in amplitude, with approximately symmetric 
E and R spikes phases (this worm was tailfirst in the channel so E 
spikes are downward in the figure). In response to 0.1 µM 
ivermectin, the rhythm began to exhibit gaps that lengthened 
progressively over time, resulting in intermittent bouts of 
pumping. Pumping frequency within each bout decreased 
moderately over time, as did spike amplitude.  Eventually only 
isolated pumps dominated by the E spike remained.  
Figure 6. Effect of ivermectin on peak-to-peak EPG amplitude 
(A1), pump frequency (B1) and duration of pharyngeal action 
potentials (C1) for one representative wild type worm.  The worm 
was first perfused with control solution (M9-5HT buffer for >30 
min before switching to 0.1 µM ivermectin containing 0.005% 
Fast Green as a visual marker. The drug reached the worm at t = 
0. Each dot in A1, B1, C1 corresponds to a single pump as 
defined by the detection algorithm (see Experimental Methods).  
The events were divided into four time regions (−10 to −0.5 min, 
black; 0.3 to 20 min, magenta; 20 to 35 min, green; 35 to 50 min, 
blue).  The corresponding probability distributions (PDFs) for the 
data points are shown in A2, B2, C2 using the same color 
scheme.  The peak-to-peak amplitude began to decline toward 
zero ~20 min after drug application, until pumps became 
undetectable after 50 min.  The modal pumping frequency 
remained nearly constant at ~5.2 Hz (B, black and magenta) until 
~20 min after drug application, then began to decline.  At later 
times, long inter-event intervals became increasingly frequent, 
causing the modal pump frequency to switch to a much lower 
frequency (0.6 Hz) after 40 min (blue dots in B1 and blue trace in 
B2).  The duration of pharyngeal action potentials contractions 
(C) began to decline ~15 min after drug application from the 
initial modal duration of 104 ms (black and magenta) to 52 ms 
(green and blue).  Neither the frequency nor duration of action 
potentials was noticeably altered during transient epochs of 
increased amplitude (x’s in A1), which we speculate were 
probably caused by movement of the worm within the worm 
recording module.
Figure 7. Effects of ivermectin and levamisole on the EPG and 
its magnitude ||EPG||(t) in wild type and ivermectin-resistant 
mutants.  Dashed lines replace data segments obscured by 
electrical artifacts during the solution change.  A-C show 
representative EPG data from three individual worms.  D and E 
show ||EPG||(t), normalized to the value immediately before the 
solution change, and averaged across 5 or 6 worms per condition; 
grey regions show ±1 SD.  In all experiments, worms were first 
perfused with control solution (M9-5HT buffer) for >30 min 
before switching at t = 0 to a test solution that contained 3 µM 
ivermectin (A,C and colored traces in D), 10 mM levamisole 
(colored traces in E), or control solution (B, black traces in D and 
E), with 0.005% Fast Green as a visual marker in each case.  
Ivermectin-resistant worms (DA1316 avr-14(ad1302); avr-15
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Page 8 of 16 Lab on a Chip(ad1051); glc-1(pk54)) were used for panel C and for the red 
traces in D and E; all other worms were wild type.  By t = 6 min 
after exposure to ivermectin, the mean normalized ||EPG||(t) was 
significantly reduced in wild type worms (D, blue) compared to 
controls (D, black; p < 0.03; two-tailed t-test), but not in 
ivermectin-resistant mutants (D, red; p > 0.5). After 20 min 
exposure to ivermectin, ||EPG||(t) was significantly reduced in 
wild type and mutants compared to controls (p < 0.02), but 
remained significantly higher in mutants than in wild type worms 
for the duration of these ivermectin experiments (t = 60 min; p < 
0.02).  As expected, levamisole caused rapid inhibition of 
pharyngeal pumping in both wild type (E, blue) and ivermectin-
resistant (E, red) worms compared to controls (E, black; p < 
0.0001 at t = 6 min, for both comparisons).
This journal is © The Royal Society of Chemistry [year]  Journal Name, [year], [vol], 00–00  |  9
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